Galectin Therapeutics Management
Management criteria checks 3/4
Galectin Therapeutics' CEO is Joel Lewis, appointed in Sep 2020, has a tenure of 4.33 years. total yearly compensation is $963.65K, comprised of 59.5% salary and 40.5% bonuses, including company stock and options. directly owns 1.43% of the company’s shares, worth $1.15M. The average tenure of the management team and the board of directors is 3.2 years and 8.7 years respectively.
Key information
Joel Lewis
Chief executive officer
US$963.6k
Total compensation
| CEO salary percentage | 59.5% |
| CEO tenure | 4.3yrs |
| CEO ownership | 1.4% |
| Management average tenure | 3.2yrs |
| Board average tenure | 8.7yrs |
Recent management updates
Recent updates
Galectin rises as FDA approves to begin human trial of combination immunotherapy in head and neck cancer
Oct 12Galectin Therapeutics GAAP EPS of -$0.16
Aug 15Galectin: Ability To Potentially Target Unmet Medical Need
Jul 11Galectin: Pursuing A Subset In The NASH Space
Jul 01Read This Before Buying Galectin Therapeutics, Inc. (NASDAQ:GALT) Shares
Feb 25
Is Galectin Therapeutics (NASDAQ:GALT) In A Good Position To Deliver On Growth Plans?
Jan 21How Much Of Galectin Therapeutics, Inc. (NASDAQ:GALT) Do Insiders Own?
Dec 09Galectin Therapeutics reports Q3 results
Nov 09CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$45m |
| Jun 30 2024 | n/a | n/a | -US$48m |
| Mar 31 2024 | n/a | n/a | -US$45m |
| Dec 31 2023 | US$964k | US$574k | -US$45m |
| Sep 30 2023 | n/a | n/a | -US$45m |
| Jun 30 2023 | n/a | n/a | -US$40m |
| Mar 31 2023 | n/a | n/a | -US$40m |
| Dec 31 2022 | US$974k | US$523k | -US$39m |
| Sep 30 2022 | n/a | n/a | -US$35m |
| Jun 30 2022 | n/a | n/a | -US$35m |
| Mar 31 2022 | n/a | n/a | -US$34m |
| Dec 31 2021 | US$1m | US$500k | -US$31m |
| Sep 30 2021 | n/a | n/a | -US$31m |
| Jun 30 2021 | n/a | n/a | -US$29m |
| Mar 31 2021 | n/a | n/a | -US$26m |
| Dec 31 2020 | US$1m | US$165k | -US$24m |
| Sep 30 2020 | n/a | n/a | -US$21m |
| Jun 30 2020 | n/a | n/a | -US$18m |
| Mar 31 2020 | n/a | n/a | -US$15m |
| Dec 31 2019 | US$189k | n/a | -US$20m |
| Sep 30 2019 | n/a | n/a | -US$18m |
| Jun 30 2019 | n/a | n/a | -US$19m |
| Mar 31 2019 | n/a | n/a | -US$20m |
| Dec 31 2018 | US$55k | n/a | -US$15m |
Compensation vs Market: Joel's total compensation ($USD963.65K) is above average for companies of similar size in the US market ($USD650.40K).
Compensation vs Earnings: Joel's compensation has been consistent with company performance over the past year.
CEO
Joel Lewis (54 yo)
4.3yrs
Tenure
US$963,647
Compensation
Mr. Joel Lewis serves as Chief Executive Officer and President at Galectin Therapeutics, Inc since September 2, 2020 and Director since December 14, 2017. He served as the Managing Director of Shareholder...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 4.3yrs | US$963.65k | 1.43% $ 1.2m | |
| CFO, Treasurer & Corporate Secretary | 11.5yrs | US$561.42k | 0.012% $ 9.7k | |
| General Counsel | no data | no data | no data | |
| Head of CMC & Pharmaceutical Development | 2yrs | no data | no data | |
| Chief Medical Officer | less than a year | no data | 0.042% $ 33.7k | |
| Executive Assistant & Officer Manager | no data | no data | no data |
3.2yrs
Average Tenure
54yo
Average Age
Experienced Management: GALT's management team is considered experienced (3.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 7.1yrs | US$963.65k | 1.43% $ 1.2m | |
| Independent Director | 15.9yrs | US$87.24k | 0.097% $ 77.6k | |
| Independent Director | 10.3yrs | US$81.74k | 0.13% $ 105.3k | |
| Independent Chairman | 7.1yrs | US$71.74k | 16.42% $ 13.2m | |
| Independent Director | 13.3yrs | US$75.24k | 0.022% $ 17.4k | |
| Co-founder & Member of the Scientific Board | no data | US$203.69k | no data | |
| Director | 5.1yrs | US$71.74k | 0.024% $ 19.5k | |
| Member of the Scientific Board | no data | no data | no data | |
| Independent Vice Chairman of the Board | 13.7yrs | US$87.74k | 0.23% $ 182.8k | |
| Member of Clinical Advisory Board | no data | no data | no data | |
| Member of Clinical Advisory Board | no data | no data | no data | |
| Independent Director | 4.3yrs | US$86.74k | 0.070% $ 56.4k |
8.7yrs
Average Tenure
74yo
Average Age
Experienced Board: GALT's board of directors are considered experienced (8.7 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/16 07:15 |
| End of Day Share Price | 2025/01/16 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Galectin Therapeutics Inc. is covered by 11 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Keay Nakae | Ascendiant Capital Markets LLC |
| Mayank Mamtani | B. Riley Securities, Inc. |
| Vernon Bernardino | Dawson James Securities |